Repligen | RGEN - Ordinary Share Capital



Repligen reported $562K in Ordinary Share Capital for its fiscal quarter ending in March of 2025.


Ordinary Share Capital Change Date
Agilent USD 283.59M 280.59M Jul/2025
Align Technology USD 72.48M 572K Jun/2025
Bio Techne USD 156.76M 155.19M Jun/2025
BioMarin Pharmaceutical USD 192M 191.81M Jun/2025
Bristol-Myers Squibb USD 2.04B 1.74B Jun/2025
Bruker USD 151.72M 149.92M Jun/2025
Charles River Laboratories USD 49.21M 48.7M Jun/2025
Danaher USD 715.9M 706.9M Jun/2025
Dentsply International USD 199.3M 196.3M Jun/2025
Exact Sciences USD 189.22M 187.33M Jun/2025
General Electric Aerospace USD 1.06B 1.05B Jun/2025
Henry Schein USD 121.9M 120.9M Jun/2025
Illumina USD 154M 152M Jun/2025
IQVIA Holdings USD 170M 167.42M Jun/2025
Mettler Toledo International USD 20.6M 20.15M Jun/2025
Myriad Genetics USD 900K 0 Mar/2025
Pfizer USD 5.68B 5.2B Jun/2025
Repligen USD 562K 1000 Mar/2025
Revvity USD 117.87M 2.78M Jun/2025
Standard Biotools USD 381.69M 381.3M Jun/2025
Thermo Fisher Scientific USD 377.49M 66.51M Jun/2025
Waters USD 59.51M 57.88M Jun/2025
West Pharmaceutical Services USD 71.9M 53.1M Jun/2025